Clofazimine inhalation - MannKind Corporation
Alternative Names: MNKD-101; MNKD-102; QRM-003; QRM-007Latest Information Update: 23 Mar 2026
At a glance
- Originator Qrumpharma
- Developer MannKind Corporation
- Class Antibacterials; Antileprotics; Phenazines
- Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
-
Orphan Drug Status
Yes - Nontuberculous mycobacterium infections
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Nontuberculous mycobacterium infections
Most Recent Events
- 06 Mar 2026 Discontinued - Phase-I for Nontuberculous mycobacterium infections in USA (Inhalation)
- 06 Mar 2026 Discontinued - Phase-III for Nontuberculous mycobacterium infections (Adjunctive treatment) in Australia (Inhalation)
- 06 Mar 2026 Discontinued - Phase-III for Nontuberculous mycobacterium infections (Adjunctive treatment) in Japan (Inhalation)